Hand-foot syndrome (HFS) is a dose-limiting side effect of capecitabine. Celecoxib prevents HFS by inhibiting cyclooxygenase-2 (COX-2) that is upregulated because of the underlying associated ...

Background Capecitabine (Xeloda®) is a cytotoxic, antimetabolite chemotherapeutic agent. Its most common adverse events are diarrhea, hand-foot syndrome (HFS), hyperbilirubinemia, hyperpigmentation, ...

The common side effect of hand-foot syndrome seen in patients taking capecitabine can be prevented by a cheap and safe topical gel containing 1% diclofenac, researchers reported in a study that ...

Results showed 23 patients in the capecitabine maintenance group (44.2%) experienced disease progression or died compared with 37 (71.2%) in the best supportive care group at median follow-up of ...

Hand-foot syndrome is a severe skin reaction caused by some chemotherapy drugs, including Xeloda. It affects the soles of your feet, the palms of your hands, or both.

Context Certain chemotherapy drugs, notably capecitabine, can cause a side effect known as palmar-plantar erythrodysesthesia (hand-foot syndrome), a painful swelling and inflammation of the hands ...

Some of the issues with this regimen included adverse events, like diarrhea, and skin reactions, including hand-foot syndrome, that we can see with capecitabine.

In contrast, patients treated with Xeloda alone were more likely to develop hand-foot syndrome (swelling, redness and pain of the hands and feet) compared with those treated with tesetaxel plus Xeloda ...

Journal reference: Ruiz-Pinto, S., et al. (2020) Regulatory CDH4 Genetic Variants Associate With Risk to Develop Capecitabine‐Induced Hand‐Foot Syndrome.